Alerus Financial NA Sells 4,440 Shares of Cencora, Inc. (NYSE:COR)

Alerus Financial NA lowered its position in Cencora, Inc. (NYSE:COR) by 11.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 33,896 shares of the company’s stock after selling 4,440 shares during the quarter. Alerus Financial NA’s holdings in Cencora were worth $7,616,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Hickory Asset Management Inc. purchased a new stake in shares of Cencora in the 4th quarter valued at about $572,000. Sylvest Advisors LLC bought a new stake in shares of Cencora during the 4th quarter worth $1,105,000. Insight Wealth Strategies LLC grew its position in Cencora by 124.6% in the fourth quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock worth $4,549,000 after acquiring an additional 11,232 shares in the last quarter. Vontobel Holding Ltd. increased its stake in Cencora by 46.9% in the fourth quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company’s stock valued at $1,403,000 after acquiring an additional 1,995 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. raised its position in Cencora by 71.1% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company’s stock valued at $1,583,000 after purchasing an additional 2,928 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

Shares of COR stock opened at $274.33 on Friday. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $274.93. The stock has a market cap of $53.20 billion, a price-to-earnings ratio of 39.02, a PEG ratio of 1.31 and a beta of 0.51. The business’s fifty day moving average is $253.15 and its 200 day moving average is $240.91. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.80%. The ex-dividend date was Friday, February 14th. Cencora’s payout ratio is currently 31.29%.

Analyst Ratings Changes

A number of research analysts have commented on COR shares. JPMorgan Chase & Co. increased their price target on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Wells Fargo & Company raised their target price on shares of Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a report on Friday, March 14th. StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Evercore ISI upped their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Finally, Mizuho started coverage on Cencora in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $280.20.

Insider Buying and Selling

In other news, Chairman Steven H. Collis sold 14,578 shares of the business’s stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the completion of the transaction, the chairman now directly owns 317,913 shares of the company’s stock, valued at $85,680,732.63. The trade was a 4.38 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Silvana Battaglia sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares in the company, valued at $3,724,197.76. This represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,675 shares of company stock worth $8,034,778. 10.80% of the stock is owned by corporate insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.